{"id":"euvax-b-hepatitis-b-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or soreness"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2109163","moleculeType":"Vaccine component"},"_fixedAt":"2026-03-30T16:05:25.756472","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is an inactivated hepatitis B vaccine containing recombinant hepatitis B surface antigen (HBsAg) produced in yeast cells. Upon administration, it triggers both humoral and cellular immune responses, leading to the production of anti-HBs antibodies that neutralize the virus and provide long-term immunity against hepatitis B infection.","oneSentence":"Euvax B stimulates the immune system to produce antibodies against hepatitis B virus surface antigen, providing protection against hepatitis B infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:49.069Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis B infection in infants, children, and adults"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT02697474","phase":"PHASE3","title":"Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-02","conditions":"Hepatitis B","enrollment":150},{"nctId":"NCT03110757","phase":"PHASE1","title":"A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-05-20","conditions":"Schistosomiasis","enrollment":60},{"nctId":"NCT02094833","phase":"PHASE3","title":"DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-03","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":310}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Euvax B®"],"phase":"phase_3","status":"active","brandName":"Euvax B®: Hepatitis B vaccine","genericName":"Euvax B®: Hepatitis B vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"Euvax B stimulates the immune system to produce antibodies against hepatitis B virus surface antigen, providing protection against hepatitis B infection. Used for Prevention of hepatitis B infection in infants, children, and adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}